PMID- 17629092
OWN - NLM
STAT- MEDLINE
DCOM- 20070830
LR  - 20131121
IS  - 0172-6390 (Print)
IS  - 0172-6390 (Linking)
VI  - 54
IP  - 76
DP  - 2007 Jun
TI  - Eradication rates of helicobacter pylori infection with second-line treatment: 
      non-ulcer dyspepsia compared to peptic ulcer disease.
PG  - 1293-6
AB  - BACKGROUND/AIMS: Initial proton pump inhibitor (PPI)-based triple therapy for 
      Helicobacter pylori (H. pylori) infection is less effective in patients with 
      nonulcer dyspepsia (NUD) than those with peptic ulcer disease (PUD). To date, 
      there have been no studies on the difference in eradication rates in NUD compared 
      to PUD with regard to second-line therapy. Therefore, we retrospectively analyzed 
      the difference in eradication rates of a second-line quadruple therapy for NUD 
      and PUD patients. METHODOLOGY: Between June 2003 and December 2005, patients who 
      failed to respond to initial PPI-based triple therapy, received 7 days of 
      quadruple therapy (PPI b.i.d., bismuth 300mg q.i.d., metronidazole 500mg t.i.d., 
      tetracycline 500mg q.i.d.) as a second-line treatment regimen. Four weeks after 
      the completion of the course of medication, a 13C-urea breath test was performed 
      for detection of H. pylori. RESULTS: A total of 87 patients received second-line 
      quadruple therapy. Of these, 43 patients had NUD and 44 patients had PUD (19 
      gastric ulcers, 23 duodenal ulcers, 2 both ulcers). The eradication rates were 
      76.7% (33/43) in the NUD group and 90.9% (40/44) in the PUD group by per-protocol 
      analysis. Therefore, the eradication rates in the NUD group were significantly 
      lower than those in the PUD group (p = 0.034). CONCLUSIONS: A 7-day bismuth-based 
      second-line quadruple therapy for H. pylori infection was less effective in 
      patients with NUD than those with PUD. Therefore, a more potent second-line 
      treatment regimen or extension of treatment duration of quadruple therapy should 
      be considered for the eradication of H. pylori in patients with NUD.
FAU - Chung, Su Jin
AU  - Chung SJ
AD  - The Liver Research Institute, Department of Internal Medicine, Seoul National 
      University College of Medicine, Seoul, Korea.
FAU - Lee, Dong Ho
AU  - Lee DH
FAU - Kim, Nayoung
AU  - Kim N
FAU - Jung, Sook Hyang
AU  - Jung SH
FAU - Kim, Jin Wook
AU  - Kim JW
FAU - Hwang, Jin Hyeok
AU  - Hwang JH
FAU - Park, Young Soo
AU  - Park YS
FAU - Lee, Kwang Hyuk
AU  - Lee KH
FAU - Jung, Hyun Chae
AU  - Jung HC
FAU - Song, In Sung
AU  - Song IS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Greece
TA  - Hepatogastroenterology
JT  - Hepato-gastroenterology
JID - 8007849
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Organometallic Compounds)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 140QMO216E (Metronidazole)
RN  - HS813P8QPX (bismuth tripotassium dicitrate)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use
MH  - Adult
MH  - Aged
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Dyspepsia/*drug therapy/microbiology
MH  - Female
MH  - Helicobacter Infections/*drug therapy
MH  - Helicobacter pylori/isolation & purification
MH  - Humans
MH  - Lansoprazole
MH  - Male
MH  - Metronidazole/therapeutic use
MH  - Middle Aged
MH  - Omeprazole/therapeutic use
MH  - Organometallic Compounds/therapeutic use
MH  - Peptic Ulcer/*drug therapy/microbiology
MH  - *Proton Pump Inhibitors
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2007/07/17 09:00
MHDA- 2007/08/31 09:00
CRDT- 2007/07/17 09:00
PHST- 2007/07/17 09:00 [pubmed]
PHST- 2007/08/31 09:00 [medline]
PHST- 2007/07/17 09:00 [entrez]
PST - ppublish
SO  - Hepatogastroenterology. 2007 Jun;54(76):1293-6.